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Abstract
FTY720 is a new and effective immunosuppressive agent, which
produces peripheral blood lymphopenia through a lymphocyte
homing effect. We investigated the relationship between the dose
of FTY720 or blood concentration (pharmacokinetics, PK) and
peripheral lymphopenia (pharmacodynamics, PD) in 23 kidney trans-
plant recipients randomized to receive FTY720 (0.25-2.5 mg/day) or
mofetil mycophenolate (2 mg/day) in combination with cyclosporine
and steroids. FTY720 dose, blood concentrations and lymphocyte
counts were determined weekly before and 4 to 12 weeks after
transplantation. The effect of PD was calculated as the absolute
lymphocyte count or its reductions. PK/PD modeling was used to
find the best-fit model. Mean FTY720 concentrations were 0.36 ±
0.05 (0.25 mg), 0.73 ± 0.12 (0.5 mg), 3.26 ± 0.51 (1 mg), and 7.15 ± 1.41
ng/ml (2.5 mg) between 4 and 12 weeks after transplantation. FTY720
PK was linear with dose (r2 = 0.98) and showed low inter- and intra-
individual variability. FTY720 produced a dose-dependent increase
in mean percent reduction of peripheral lymphocyte counts (38 vs
42 vs 56 vs 77, P < 0.01, respectively). The simple Emax model
[E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for
FTY720 dose (Emax = 87.8 ± 5.3% and ED50 = 0.48 ± 0.08 mg, r2 = 0.94)
or concentration (Emax = 78.3 ± 2.9% and EC50 = 0.59 ± 0.09 ng/ml,
r2 = 0.89) vs effect (% reduction in peripheral lymphocytes). FTY720
PK/PD is dose dependent and follows an Emax model (EC50 = 0.5 mg
or 0.6 ng/ml). Using lymphopenia as an FTY720 PD surrogate
marker, high % reductions (~80%) in peripheral lymphocytes are
required to achieve best efficacy to prevent acute allograft rejection.
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Introduction
FTY720 (2-amino-2-[2-(4-octylphenyl)
ethyl] propane-1,3 diol hydrochloride) is a
novel immunomodulator agent developed by
a chemical modification of myriocine (1-3),
a metabolite isolated from Iscaria sinclairii
broth (4). This immunomodulator is effec-
tive in protecting solid organ grafts from
acute rejection in experimental transplant
models (5). FTY720 is effective even in the
absence of cyclosporine, and also shows
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synergistic interactions with cyclosporine,
tacrolimus, sirolimus, or everolimus (6-14).
FTY720 is currently undergoing phase III
clinical trials in kidney transplant recipients
after FTY720 doses and combination thera-
py were identified in phase II studies.
FTY720 produces peripheral lymphope-
nia in both animals and humans as a conse-
quence of altered T-cell trafficking and redi-
rection to secondary lymphatic organs (15,
16). At therapeutic concentrations, FTY720
does not interfere with cytokine synthesis or
binding, does not inhibit cell proliferation and
does not cause cell death by apoptosis (17,18).
Lymphopenia is fully reversible upon drug
discontinuation (19). FTY720 needs to be
phosphorylated by sphingosine phosphatase
and the phosphorylated form (FTY720-P)
appears to mediate its biological effect through
the binding to sphingosine-1-phosphate, G-
protein-coupled receptors expressed in the
membrane of lymphocytes and endothelial
cell of lymph nodes (20-22). The proposed
molecular mechanism of action is that lym-
phocyte homing is altered by FTY720 as a
sphingosine-1-phosphate agonist targeting
G-protein-coupled receptors expressed in
the membrane of lymphocytes and endothe-
lial cell of lymph nodes (23). This binding
results in drug-receptor internalization, in-
creasing intrinsic lymphocyte mobility and
chemotactic response, accelerating lympho-
cyte homing, and trapping in secondary lym-
phoid tissues (21,24).
FTY720 has unique pharmacokinetic
properties. Its absorption is slow, reaching
peak concentrations 8 to 36 h after oral
administration (19). FTY720 has a large
volume of distribution (1116-1737 L) and a
clearance of about 123 to 383 ml/min, result-
ing in a long elimination half-life of about 108
h (4.5 days) (19). Since it is given once a day,
presumably it takes about 4 weeks to reach
steady-state concentration, with 11- to 19-
fold accumulation in tissues compared to
first dose administration (19).
Pharmacokinetic and pharmacodynamic
(PK/PD) modeling has been used increas-
ingly in clinical pharmacology and drug de-
velopment, not only to speed up the develop-
ment process but, more importantly, to de-
termine the optimal dosage of new drugs,
which will deliver an appropriate effect. The
relationship between FTY720 pharmacoki-
netics and pharmacodynamics has been stud-
ied in various experimental transplant models
(13). The aim of the present study was to
determine the relationship among FTY720
dose, blood concentration and surrogate bio-
logical effect in the peripheral blood com-
partment (lymphopenia). This information
will help to choose and possibly individualize
drug dose regimens, which will result in best
efficacy/toxicity relationships.
Material and Methods
Population
Between June 1st and September 30,
2000, 23 kidney transplant recipients were
enrolled at our center as part of an interna-
tional multicenter prospective, open-label,
randomized, dose-finding, and exploratory
trial, which included 208 patients. The pri-
mary objective was to evaluate the safety,
tolerability and preliminary efficacy of in-
creasing doses of FTY720 versus mofetil
mycophenolate (MMF, CellCept®, Roche
Laboratories, New Jersey, NJ, USA) in com-
bination with a cyclosporine microemulsion
and prednisone.
The local Medical Ethics Committee ap-
proved the protocol and the study was per-
formed in accordance with the Declaration of
Helsinki and US Food and Drug Administration
guidelines for good clinical practice. All pa-
tients signed an informed consent term after
being informed of the details of this study, and
were enrolled according to study-specific in-
clusion and exclusion criteria. The present
report describes a retrospective analysis of
data obtained from 23 patients enrolled at our
transplant center during the clinical trial.
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Study design
The study involved 24 weeks of observa-
tion divided into 12 weeks of treatment and
12 weeks of follow-up. Patients were ran-
domized 24 h after renal transplantation to
one of four FTY720 groups (0.25 mg (N =
4), 0.5 mg (N = 4), 1 mg (N = 5), 2.5 mg (N
= 5)) or to one MMF group (N = 5). To be
enrolled in the study patients had to be
between 18 and 65 years old and to be
receiving their first living or cadaver donor
allografts. All patients received initial doses
of cyclosporine of 8 to 10 mg kg-1 day-1
twice a day adjusted to achieve therapeutic
concentrations of 200-400 ng/ml during the
first month, 150-250 ng/ml during the sec-
ond and third months, and 100-200 ng/ml
thereafter. Prednisone was introduced two
days after the transplant, with initial doses of
0.5 mg kg-1 day-1 followed by a gradual
reduction to 0.2 mg kg-1 day-1 at 12 weeks
post-transplant. Within 24 h after transplant
surgery, a loading dose of 1, 2, 4, and 4 mg
was administered to patients randomized to
receive fixed maintenance doses of 0.25,
0.5, 1, or 2.5 mg/day of FTY720. Patients
randomized to the MMF group received 2 g
twice a day. FTY720 treatment lasted 12
weeks with the patients being converted to
azathioprine, 2 mg kg-1 day-1, or MMF, 2 g/
day thereafter at the discretion of the inves-
tigator. Drug doses were also adjusted for
safety and tolerance.
Pharmacokinetics/pharmacodynamics
There were 14 study visits, namely pre-
transplant and at 1, 2, 4 to 12 weeks during
the treatment phase and 16, 20 and 24 weeks
during the follow-up phase. On the occasion
of each study visit, blood samples were
obtained to measure blood concentrations of
cyclosporine and FTY720 and to perform
lymphocyte counts.
Pharmacokinetic analysis. Whole blood
cyclosporine concentrations were measured
daily during the first week and doses were
adjusted until therapeutic concentrations
(>200 ng/ml) were achieved. Subsequent
monitoring was performed twice a week
during the first month, once a week during
the second month, and every other week
thereafter. Whole blood cyclosporine con-
centrations were measured by a fluores-
cence polarization immunoassay (Abbott
Laboratories, Chicago, IL, USA) according
to the manufacturer instructions. Since
FTY720 has a long terminal half-live of about
100 h, steady-state concentrations are
achieved only after 4 weeks of treatment.
Therefore, blood samples were collected to
measure whole blood FTY720 concentra-
tions between 4 and 12 weeks. Blood con-
centrations of FTY720 were determined us-
ing a validated HPLC/mass spectrometry/
mass spectrometry method from Novartis
(East Hanover, NJ, USA).
Pharmacodynamics study. The surrogate
marker of the pharmacodynamic effect of
FTY720 used in this study was the peripheral
lymphocyte count in the blood compart-
ment. Lymphocyte counts were performed
on the occasion of each study visit (pre-
transplant and 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12,
16, 20, and 24 weeks after transplant) in all
5 groups using the CELL-DYN 3200 auto-
matic counter (Abbott Park, Chicago, IL,
USA) whose methods of determinations are
based on flow cytometry. Since MMF has no
effect on peripheral lymphocytes (25), lym-
phocyte counts obtained from patients re-
ceiving MMF were used to calculate the
basal pharmacodynamic effect when FTY720
doses or exposures were equal to zero. The
pharmacodynamic effect of FTY720 was
determined either as absolute reduction in
peripheral lymphocyte counts or as percent
reduction compared to the lymphocyte count
obtained pre-transplant and before the ad-
ministration of the first dose of FTY720 or
MMF.
PK/PD correlations. Peripheral lympho-
cyte counts were correlated with FTY720
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doses and blood concentrations. PK/PD
modeling was used to find the best-fit model
of the correlation between absolute or per-
cent reduction in peripheral lymphocyte count
and increasing doses or blood concentra-
tions of FTY720. For these analysis we used
the scientific software WinNonlin (SCI Soft-
ware) to find the best fit PK/PD model that
explains the relationship between FTY720
dose or blood concentration and the chosen
pharmacodynamic surrogate marker.
Statistical analysis
Demographic characteristics were ana-
lyzed by analysis of variance (ANOVA) for
continuous variables and by the chi-square
test for categorical variables. Summary sta-
tistics were expressed as means ± SD, or
frequencies or median and range, respective-
ly. The observed and calculated PK/PD pa-
rameters were presented as means ± SD and
as dose/response and exposure/response re-
lationships. Linear regression analyses were
used to correlate FTY720 dose and blood
concentration. Nonlinear regressions were
used to correlate the dose and drug concen-
tration in blood with biological response. All
statistical analyses were performed using the
SPSS 7.5 software (SPSS Inc., Chicago, IL,
USA), with the level of significance set at P
< 0.05.
Results
Demographics and baseline characteristics
Demographic characteristics of the al-
lograft recipients were similar across treat-
ment groups (Table 1). Mean age was 40.1
± 11.0 years, weight 62.2 ± 8.8 kg, and mean
body mass index was 22.8 ± 2.6 kg/m2. Most
patients were males (61%) and white (61%),
with 4 (17%) blacks and 5 (22%) with
various degrees of miscegenation. The pri-
mary etiology leading to renal failure was
chronic glomerulonephritis (22%), followed
by diabetes (17%) and nephrosclerosis
(13%). Mean number of HLA mismatches
was 2.9 ± 0.5 and 100% showed no pre-
formed anti-HLA antibodies. All recipients
tested negative for hepatitis B and C viruses
and 50% of the recipients were positive for
cytomegalovirus IgG. No significant differ-
ences in demographic characteristics were
observed between the 5 groups.
Pharmacokinetics
Cyclosporine doses and whole blood con-
centrations did not differ statistically be-
tween the 5 groups during the 24 weeks of
treatment. Mean doses/weight were 9.7 ±
2.5 in the first week, 6.5 ± 1.9 at week 4, 4.7
± 1.5 at week 12, and 3.8 ± 1.5 mg kg-1
day-1 at week 24, with no significant differ-
ences between groups (Figure 1A). Corre-
sponding mean whole blood cyclosporine
concentrations were 271.0 ± 104.1, 351.1 ±
121.4, 213.5 ± 71.3, and 149.1 ± 72.7 ng/ml,
respectively (Figure 1B). Also dose-normal-
ized cyclosporine concentrations did not dif-
fer significantly between the 5 groups, rang-
ing from 0.50 ± 0.35  at week 1 to 0.63 ± 0.30
ng ml-1 mg-1 at week 24. Therapeutic con-
centrations of cyclosporine were achieved in
all groups during the study period. Mean
prednisone doses were 30.4 ± 3.7 (week 1),
27.3 ± 3.7 (week 4), 13.3 ± 3.7 (week 12),
and 9.9 ± 0.5 mg/day (week 24), with no
significant differences between the 5 groups.
Mean FTY720 blood concentrations ac-
cording to dose level and study visit are
shown in Figure 2. There were no significant
differences in mean blood concentration be-
tween study visits (General Linear Model for
repeated measurements) within each dose
level, confirming that at week 4 steady-state
FTY720 concentrations had been achieved
(Table 2). Interindividual variability (% coef-
ficients of variation, %CV) increased from
24 to 41% with increasing doses of FTY720
(P = 0.05) but no significant differences
were observed between study visits. Aver-
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Table 1. Demographic characteristics of the transplant population.
Total FTY720 FTY720 FTY720 FTY720 MMF
(0.25 mg) (0.5 mg) (1 mg) (2.5 mg) (2 g)
N 23 4 4 5 5 5
Age (years) 40.1 ± 11.0 45.5 ± 5.0 38.3 ± 14.0 40.4 ± 14.3 38.6 ± 11.8 38.6 ± 10.7
(23.0-59.0) (40.0-52.0) (23.0-52.0) (24.0-59.0) (24.0-57.0) (25.0-52.0)
Gender (male/female) 14/9 3/1 3/1 0/5 4/1 4/1
Weight (kg) 62.2 ± 8.8 68.6 ± 10.1 60.4 ± 5.6 55.6 ± 7.5 61.8 ± 10.4 65.4 ± 7.2
(47.4-83.6) (62.3-83.6) (53.1-65.9) (47.4-61.8) (53.8-79.7) (57.6-76.0)
BMI (kg/m2) 22.8 ± 2.6 24.7 ± 2.2 22.1 ± 1.7 23.9 ± 3.8 21.5 ± 2.0 22.0 ± 2.5
(19.2-27.0) (22.3-27.0) (20.5-24.2) (19.2-27.0) (20.1-24.9) (19.7-26.0)
Ethnicity (white/black/mulatto/others) 14/4/2/3 3/0/0/1 4/0/0/0 2/1/1/1 3/1/0/1 2/2/1/0
HLA mismatches 2.9 ± 0.5 3.3 ± 0.5 3.0 ± 0.0 2.6 ± 0.5 2.8 ± 0.4 2.9 ± 0.5
Cause of ESRD
Chronic glomerulonephritis 5 (21.7%) 2 1 0 1 1
Nephrosclerosis 3 (13.0%) 0 0 1 1 1
Polycystic kidney disease 2 (8.9%) 0 0 0 1 1
Diabetic nephropathy 4 (17.4%) 1 1 1 0 1
Unknown 9 (39.1%) 1 2 3 2 1
Time on dialysis (months) 17.7 ± 10.2 22.3 ± 12.9 18.5 ± 4.9 20.0 ± 13.6 16.2 ± 11.3 12.6 ± 6.8
(2.0-36.0) (6.0-36.0) (12.0-24.0) (2.0-36.0) (7.0-36.0) (5.0-23.0)
Panel reactive antibody <5/>5 (%) 23/0 4/0 4/0 5/0 5/0 5/0
Viral status
Anti-HCV positive (IgG) 0 0 0 0 0 0
HbsAg positive 0 0 0 0 0 0
CMV positive (IgG) 12 3 1 2 3 3
Data are reported as means ± SD (range). MMF = mofetil mycophenolate; BMI = body mass index; HLA = human leukocyte antigen; ESRD
= end-stage renal disease; HCV = hepatitis C virus; CMV = cytomegalovirus. Panel reactive antibody between donor and recipients greater or
less than 5%.
Figure 1. Time course of mean cyclosporine doses (A) and blood concentrations (B). There were no significant differences for mean cyclosporine
doses or blood concentrations among study groups at each visit (independent Student t-test). MMF = mofetil mycophenolate.
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age intra-individual variability (%CV) ranged
from 25 to 28 and was not dose dependent.
In the 10-fold dose range studied in this trial
(0.25 to 2.5 mg/day), FTY720 pharmacoki-
netics was linear with dose (r2 = 0.679 and
0.982), as can be observed in Figure 3.
Pharmacodynamics
The time course of the FTY720-induced
reduction of peripheral lymphocyte count is
shown in Figure 4. There were no significant
differences in pre-transplant values between
groups and lymphopenia was not observed in
the MMF group throughout the study. The
Figure 2. Time course of mean FTY720 blood concentrations between 4 and 12 weeks
post-transplant. P < 0.01 for 1.0 and 2.5 mg FTY720 compared to 0.25 and 0.5 mg
FTY720 during administration time (ANOVA).
Figure 3. Linear regression analysis correlating individual (A) or mean (B) FTY720 blood concentrations and dose levels.
Table 2. FTY720 blood concentrations and percent coefficient of variation (%CV) between weeks 4 and 12 according to FTY720 dose level.
Visit (week) FTY720 (0.25 mg) FTY720 (0.50 mg) FTY720 (1.00 mg) FTY720 (2.50 mg)
N = 4 N = 4 N = 5 N = 5
4a 0.41 ± 0.13 (32) 0.81 ± 0.13 (16) 2.59 ± 1.08 (42) 4.26 ± 1.65 (39)
5a 0.37 ± 0.12 (32) 0.78 ± 0.16 (21) 3.18 ± 1.35 (42) 6.25 ± 2.80 (45)
6a 0.26 ± 0.05 (14) 0.72 ± 0.26 (26) 3.74 ± 2.51 (67) 6.60 ± 1.82 (29)
7a 0.36 ± 0.16 (44) 0.81 ± 0.25 (31) 3.77 ± 1.39 (37) 6.61 ± 1.81 (27)
8a 0.37 ± 0.01 (3) 0.80 ± 0.36 (45) 3.31 ± 1.05 (32) 7.36 ± 2.58 (36)
9a 0.43 ± 0.11 (26) 0.79 ± 0.25 (32) 3.44 ± 1.53 (44) 9.02 ± 2.82 (32)
10a 0.33 ± 0.07 (21) 0.76 ± 0.31 (41) 3.37 ± 0.66 (20) 8.00 ± 2.56 (32)
11a 0.37 ± 0.09 (24) 0.66 ± 0.27 (41) 3.65 ± 1.09 (30) 8.24 ± 4.17 (51)
12a 0.35 ± 0.08 (23) 0.44 ± 0.30 (68) 2.28 ± 1.22 (54) 7.97 ± 4.05 (51)
Total a 0.36 ± 0.05 (24) 0.73 ± 0.12 (36) 3.26 ± 0.51 (41) 7.15 ± 1.41 (38)
Average interindividual %CVb,c (range) 24 ± 12 (14-44) 36 ± 15 (16-68) 41 ± 14 (20-67) 38 ± 9 (27-51)
Average intra-individual %CVd (range) 25 ± 14 (7-40) 26 ± 16 (12-42) 25 ± 8 (17-35) 28 ± 13 (14-49)
Data are reported as means ± SD in ng/ml and %CV within parentheses.
aFTY720 blood level, P < 0.05 between groups (ANOVA); binterindividual %CV according to FTY720 dose, P = 0.05 (ANOVA); cinterindividual
%CV according to visit, P > 0.05 (general linear model for repeated measures); dintra-individual %CV, P > 0.05 between groups (ANOVA).
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reduction in the number of lymphocytes was
observed as early as at week 1, reached its
peak at about week 4, and was fully reversed
4 to 8 weeks after treatment interruption.
The extent of lymphopenia and the time to
return to baseline values appear to depend on
the magnitude of the FTY720 dose. Mean
percent reduction in lymphocyte counts af-
ter week 4 was dose dependent (37.8 ± 19.2
(0.25 mg) vs 42.4 ± 19.9 (0.50 mg) vs 56.0
± 17.8 (1.00 mg) vs 76.5 ± 10.8% (2.50 mg),
P < 0.01). Mean lymphocyte counts varied
from 624 to 1320 (0.25 mg), 675 to 1085
(0.5 mg), 567 to 853 (1 mg), and 327 to 696/
mm3 (2.5 mg; Table 3). Inter- (42-55%) and
intra-individual variability (25-55%) ranges
Figure 4. Time course of FTY720-induced lymphopenia during the 12-week treatment
phase and return to baseline values upon drug discontinuation. MMF = mofetil myco-
phenolate.
Table 3. Mean peripheral blood lymphocyte counts and percent lymphocyte reduction between weeks 4 and 12 in the 5 groups of patients.
MMF (2 g) FTY720 (0.25 mg) FTY720 (0.5 mg) FTY720 (1 mg) FTY720 (2.5 mg)
 (N = 5) (N = 4) (N = 4) (N = 5) (N = 5)
Visit  (week)
Lymphocytes % Lymphocytes % Lymphocytes % Lymphocytes % Lymphocytes %
(N/mm3) Reduction (N/mm3) Reduction (N/mm3) Reduction (N/mm3) Reduction (N/mm3)  Reduction
Baseline
0 1746 (35) - 1677 (21) - 1372 (26) - 1567 (38) - 1657 (29) -
FTY720 treatment
4a 2488 (8) - 872 (44) 39.3 (49) 675 (45) 58.2 (3) 567 (49) 65.1 (32) 511 (53) 79.6 (6)
5a 2059 (45) - 624 (59) 46.6 (66) 805 (69) 52.6 (4) 674 (61) 59.0 (43) 459 (68) 82.6 (12)
6a 2217 (34) - 1559 (61) 39.2 (23) 852 (30) 46.9 (48) 953 (33) 43.6 (47) 327 (21) 79.5 (11)
7a 2344 (28) - 900 (75) 43.8 (49) 890 (35) 44.1 (61) 588 (50) 62.9 (34) 663 (33) 69.9 (10)
8a 2556 (26) - 1067 (81) 38.5 (32) 981 (75) 45.9 (62) 853 (41) 52.6 (8) 562 (60) 75.5 (19)
9a 2518 (25) - 1023 (98) 49.2 (40) 837 (35) 46.8 (41) 845 (46) 48.8 (45) 645 (88) 78.8 (12)
10a 2209 (27) - 1284 (12) 19.5 (94) 1085 (28) 23.4 (84) 800 (42) 52.3 (33) 696 (70) 74.0 (13)
11a 2474 (24) - 1320 (20) 15.1 (42) 934 (36) 45.8 (42) 724 (17) 53.4 (45) 545 (52) 76.9 (11)
12a 2472 (46) - 924 (12) 26.1 (4) 1271 (45) 18.6 (44) 650 (41) 62.6 (14) 623 (53) 70.9 (29)
4-12a 2364 (28) - 823 (42) 37.8 (56) 906 (49) 42.4 (47) 731 (41) 56.0 (32) 429 (37) 76.5 (14)
Average 29 ± 11 - 51 ± 31 44 ± 26 44 ± 17 43 ± 26 42 ± 12 33 ± 14 55 ± 20 17 ± 7
interindividual [8-46] [12-98]    [4-94] [28-75] [3-84] [17-61] [8-47] [21-88] [6-29]
%CVb,c [range]
Average 22 ± 7 - 55 ± 27 36 ± 8 28 ± 14 42 ± 9 25 ± 14 18 ± 12 35 ± 15 10 ± 7
 intra-individual [16-32] [21-86] [27-45] [12-47] [31-53] [13-46] [2-28] [21-59] [2-53]
%CVd [range]
Recovery
16 1740 (31) - 1717 (39) - 2520 (52) - 1968 (46) - 1220 (28) -
20 1744 (19) - 1848 (31) - 1770 (32) - 1945 (48) - 1730 (23) -
24 1853 (19) - 1720 (43) - 2080 (41) - 2128 (33) - 1620 (25) -
Percent coefficient of variation (%CV) is reported within parentheses. aLymphocyte count and reduction, P < 0.05 between groups (ANOVA); binterindividual %CV
according to group, P > 0.05 for lymphocyte count, and P < 0.01 for reduction (ANOVA); cinterindividual %CV according to visit, P > 0.05 (general linear model for
repeated measures); dintra-individual %CV according to group, P > 0.05 for lymphocyte count and P < 0.01 for reduction (ANOVA).
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Figure 6. Pharmacokinetic and pharmacodynamic inhibitory Emax model correlating FTY720 dose (A) or blood concentration (B) with absolute
lymphocyte counts in peripheral blood.
Figure 5. Linear regression analysis correlating mean FTY720-induced reduction of peripheral lymphocyte counts and drug dose (A) or
concentrations (B).
Figure 7. Pharmacokinetic and pharmacodynamic simple Emax model correlating FTY720 dose (A) or blood concentration (B) with percent reduction
in lymphocyte counts in peripheral blood.
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of absolute lymphocyte counts did not differ
according to FTY720 dose level. However, a
decrease in both inter- (44-17%) and intra-
individual variability (42-10%) ranges of per-
cent reduction in lymphocyte counts ac-
cording to FTY720 dose level was observed
(P < 0.01). There was no significant differ-
ence in interindividual %CV according to
study visit.
PK/PD analysis
The observed linear correlation between
FTY720 dose and steady-state blood con-
centrations did not translate into linear corre-
lations between dose or blood concentra-
tions and lymphopenia. In the 10-fold dose
range studied in this trial (0.25 to 2.5 mg/day)
FTY720 pharmacodynamics was not dose-
linear (r2 = 0.57 and 0.53), as can be ob-
served in Figure 5A and B. Searching for a
best-fit model we identified the inhibitory
Emax model as the one with best prediction of
the relationship between both FTY720 dose
or blood concentrations and absolute periph-
eral lymphocyte count. This model applies
the following formula: E = Emax - (Emax - E0)
* [C/(C + EC50)], where E is the pharmaco-
dynamic effect at a given drug dose or
concentration (C), Emax is the maximum phar-
macodynamic effect attributed to the drug,
E0 is the effect when drug dose or concen-
tration is equal to zero, and EC50 is the drug
dose or concentration which produces 50%
of the maximum pharmacodynamic effect.
The last parameter determines the drug po-
tency. Using this model, the correlation be-
tween individual FTY720 doses or steady-
state blood concentrations and absolute pe-
ripheral lymphocyte counts produced coef-
ficients of determination of r2 = 0.96 and r2
= 0.87, respectively. For FTY720 dose and
concentration correlations, E0 and Emax were
very similar, with EC50 of 0.08 mg or 0.13
ng/ml, respectively (Figure 6A,B). Con-
versely, the simple Emax model was the one
that best predicted the relationship between
either FTY720 dose or blood concentration
and percent reduction in peripheral lympho-
cyte count. This model applies the following
formula: E = (Emax * C)/(C + EC50), where E
is the pharmacodynamic effect at a given
drug dose or concentration (C), Emax is the
maximum pharmacodynamic effect attrib-
uted to the drug, and EC50 is the drug dose or
concentration which produces 50% of the
maximum pharmacodynamic effect. Again,
using this model, the correlation between
individual FTY720 doses or steady-state blood
concentrations and percent reduction in pe-
ripheral lymphocyte counts produced coef-
ficients of determination of r2 = 0.94 and r2
= 0.89, respectively. For FTY720 dose and
concentration correlations, Emax was 87.8%
and 78.3%, with EC50 of 0.48 mg or 0.59 ng/
ml, respectively (Figure 7A,B).
Discussion
FTY720 is a novel immunomodulating
drug with a unique mechanism of action,
which is different from the currently used
immunosuppressive agents. Results from
phase II clinical trials have demonstrated that
the combination of FTY720 with cyclo-
sporine produces a very low incidence of
acute rejection (26). Furthermore, except
for a first dose-associated mild negative
chronotropic effect, FTY720 is not nephro-
toxic, does not potentiate cyclosporine neph-
rotoxicity and lacks other specific drug-
related negative side effects (27).
In the present study, we set out to deter-
mine FTY720 PK/PD relationships in a co-
hort of patients undergoing a dose-finding
phase II clinical trial (28). The demographic
characteristics revealed a low risk transplant
population since this was an exploratory
study, but no significant differences were
observed among the study groups (Table 1).
All patients received comparable initial cy-
closporine doses and underwent similar dose
reductions resulting in virtually equal cyclo-
sporine concentrations throughout the first
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24 post-transplant weeks. Moreover FTY720
did not produce any significant drug interac-
tion with cyclosporine since blood cyclo-
sporine concentrations were similar for all
FTY720 dose groups and for the MMF
group (29).
The pharmacokinetic properties of
FTY720 have been described previously (30).
The long terminal half-life required a loading
dose to achieve steady-state concentrations
more rapidly. Except for the higher dose
level, whereby mean blood concentrations
were still increasing after week 4 (Table 2,
Figure 2), it appears that steady-state con-
centrations were achieved after 4 weeks of
daily administration. In this cohort of pa-
tients, we observed a relatively low inter- and
intra-individual variability in FTY720 trough
blood concentrations, regardless of FTY720
dose or time post-transplant. Moreover,
FTY720 showed dose-linear pharmacoki-
netics (13). Taken together, these character-
istics may result in less need for dose adjust-
ments, and fast and more predictable
achievement of target concentrations when
dose adjustments are needed.
As shown in Table 3, MMF did not
produce lymphopenia during the study pe-
riod. FTY720-induced lymphopenia began
early and could be detected as early as 1 week
after transplantation (Figure 4). Actually, in
more detailed studies, lymphopenia was al-
ready noticed after the loading dose and
paralleled the decrease in heartbeat (28). This
has been attributed to the physiological mech-
anism of action of FTY720, which, after oral
administration, is phosphorylated (FTY720-
P) and binds to sphingosine-1-phosphate
receptors present in the plasma membrane of
lymphocytes and cardiac myocytes, respec-
tively (31,32). Nadir lymphopenia is reached
between 2 and 4 weeks and after drug
discontinuation lymphocyte counts return to
baseline values within 4 to 8 weeks depend-
ing on the magnitude of the FTY720 dose.
This indicates that FTY720-induced lym-
phopenia is reversible and therefore safer,
since it does not produce prolonged apopto-
sis-related lymphopenia and does not pro-
duce long-term effects like those observed
using depleting monoclonal or polyclonal
antibodies (33). Inter- and intra-individual
variability of the peripheral absolute lympho-
cyte count is apparently higher than that seen
for the FTY720 pharmacokinetics. Inter-
and intra-individual variability of percent re-
duction of lymphocyte counts decreases
with increasing FTY720 doses, perhaps due
to achievement of maximal pharmacody-
namic effect.
Visual observation of the relationship be-
tween FTY720 doses or blood concentration
absolute lymphocyte count or percent re-
duction in lymphocyte count revealed a non-
linear pattern (Figure 3), supported by the
low coefficient of determination (r2) of the
linear regression analysis (Figure 4). Search-
ing for a best-fit model that would explain
this relationship we found two PK/PD mod-
els. For the absolute lymphocyte count, the
inhibitory Emax model was selected since
there was a decrease (inhibition) in the num-
ber of lymphocytes in peripheral blood with
increasing drug dose or concentration, show-
ing high coefficients of determinations (Fig-
ure 6). The E0 term was included to describe
the effect when drug dose or concentrations
were equal to zero (in this study, lymphocyte
counts from patients receiving MMF). For
the percent reduction in lymphocyte counts,
the simple Emax model was selected since
there was an increase in percent reduction of
the number of lymphocytes in peripheral
blood with increasing drug dose or concen-
tration, also showing high coefficients of
determination (Figure 7). There was an evi-
dent difference in EC50 between the two PK/
PD models for both FTY720 dose (0.08 vs
0.48 mg) and blood concentration (0.13 vs
0.59 ng/ml). A simple explanation for this
finding is the large but frequently observed
variability of the peripheral lymphocyte counts
when drug dose or concentrations were
equal to zero (E0 term), suggesting that the
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use of percent reduction, which naturally
corrects for baseline differences, is more
appropriate as a surrogate marker of the
pharmacodynamic effect of FTY720 in the
blood compartment.
Finally, relationships between pharmaco-
kinetics and pharmacodynamics are useful
to find ideal doses to produce the desired
effect. However, it is still important to deter-
mine the relationship between the pharmaco-
dynamic effect and efficacy and safety,
which is the ultimate goal of pharmacology.
In a phase II clinical trial, the 2.5-mg dose of
FTY720 showed good efficacy for the pre-
vention of acute rejection after kidney trans-
plantation. This dose produced a reduction
of about 80% in lymphocyte count, close to
the maximum effect (Emax). Since FTY720
accumulates 11- to 19-fold in various tis-
sues, perhaps in the secondary lymphoid
organs, which are rich in lymphocytes, and
therefore in sphingosine-1-phosphate recep-
tors, the EC50 required for drug-receptor
complex internalization might be higher.
Moreover, data from the same phase II
clinical trial demonstrated that FTY720 at
doses of 5 mg/day, which probably produce
maximum percent reduction of lymphocyte
count, is still effective and safe. Recently, it
has been demonstrated that the active form
of FTY720 is the phosphorylated form
(FTY720-P) and studies are needed to assess
the correlation between FTY720-P and the
degree of lymphopenia. Of course, the lacks
of similar dose-response curves for toxicity
impair the establishment of a therapeutic
window.
In conclusion, the PK/PD relationship of
FTY720 follows an Emax model. Using pe-
ripheral lymphopenia as an FTY720 pharma-
codynamic surrogate marker, high pharma-
codynamic effects (percent reduction in pe-
ripheral lymphocytes) are required to achieve
best efficacy, similar to what is seen in
various physiological enzymatic systems.
Further prospective studies are required to
test the clinical applicability of this strategy.
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